Background: In Japan, there have been approximately 50 000 deaths from gastric can-
| INTRODUCTION
Helicobacter pylori causes chronic gastric mucosal inflammation which underlies various disorders of the stomach, [1] [2] [3] [4] [5] including atrophic gastritis from which intestinal type gastric cancer can develop. It has also been reported that H. pylori gastritis is etiologically associated with gastroduodenal ulcers, gastric mucosa-associated lymphoid tissue lymphoma, functional dyspepsia, hyperplastic gastric polyps, idiopathic thrombocytopenic purpura, and undifferentiated gastric cancer. 2, 6, 7 The International Agency for Research on Cancer of the World Health
Organization designated H. pylori as a carcinogen for gastric cancer in 1994. 8 A multicenter randomized study performed by the Japan GAST Study Group showed that H. pylori eradication therapy decreased the incidence of secondary gastric cancer by approximately two-thirds in patients undergoing endoscopic mucosal resection of early gastric cancer, 9 demonstrating a preventive effect of H. pylori eradication therapy against gastric cancer. It has been suggested that H. pylori infection causes more than 95% of all gastric cancers in Japan and Korea. [10] [11] [12] It has long-placed emphasis on secondary prevention of gastric cancer with use of barium studies for early detection. The IARC recommended that suitable policies for preventing gastric cancer including H. pylori eradication therapy should be designed for each country worldwide. 13 Japan has long-placed emphasis on secondary prevention of gastric cancer with use of barium studies for early detection. 14 However, the number of gastric cancer deaths has remained stable at approximately 50 000 per year over the past 40 years in Japan, showing almost no change after the start of screening with barium studies. 
| METHODS

| Prescription of H. pylori eradication therapy
Prescription of H. pylori eradication therapy throughout Japan was calculated using the claims database for Hokkaido (the north island of Japan) combined with the National Database (NDB). We investigated the prescriptions for primary eradication therapy for H. pylori. The number of patients receiving primary eradication therapy throughout Japan was calculated by determining the actual number of treatment pack formulation for primary eradication using data from the NDB.
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The NDB contains information about claims and specific health examinations, and allows easy retrieval of claims data. Using the anonymized electronic medical claims in this database, we extracted the number of prescription of treatment packs for primary eradication therapy 
| Calculation of deaths from gastric cancer
The number of deaths from gastric cancer was determined from data provided by the MHLW, the National Cancer Center Japan, and the Cancer 
| RESULTS
| Prescription of H. pylori eradication therapy
The 
| Death from gastric cancer
The Helicobacter pylori eradication therapy for gastroduodenal ulcer was approved for coverage by the Japanese NHI scheme in 2000.
Subsequently, the incidence of gastroduodenal ulcer decreased dramatically by approximately 60% over 10 years, 22 and medical costs for treatment of gastroduodenal ulcer were also reduced by 47% during this period. If the incidence of H. pylori gastritis can be reduced by eradication therapy, the incidence of atrophic gastritis (a premalignant condition for gastric cancer) will also decrease. Although it is unclear whether the outcome for improvement of gastric cancer will be comparable to that for gastroduodenal ulcer, if the incidence of atrophic gastritis decreases, a reduction in the incidence of intestinal type gastric carcinoma that develops from atrophic gastritis would also be expected. 13 The present study showed that the number of deaths from gastric cancer, which has remained stable over past 40 years, decreased during the last 4 years along with an increase in the prescription of H. pylori eradication therapy. According to NHI criteria, the diagnosis of gastritis must be established by endoscopy before eradication therapy is performed and this increased requirement for endoscopy could lead to detection of gastric cancer in many patients.
The baby-boom generation is a large population that has reached the cancer-prone age over 65 years old. It was predicted that the number of deaths from gastric cancers would be 60 000 in 2020 if no new measures were taken. 22 However, the present research revealed that the annual number of deaths from gastric cancer (which remained at about 50 000 over the period of 40 years before the expansion of health insurance coverage) showed a significant decrease of about 9.2% over 4 years after expansion of the indications for H. pylori eradication. It is estimated that if patients with H. pylori infection continue to receive eradication therapy, the number of deaths from gastric cancer will be reduced by 40% to about 30 000 per year in 2020, along with a protective effect against future development of this cancer.
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